Holen Sie sich die Stockscreener-App
98.94
2.31%
1.85
Schlusskurs vom Vortag:
$97.09
Offen:
$95.08
24-Stunden-Volumen:
351.31K
Relative Volume:
0.45
Marktkapitalisierung:
$5.49B
Einnahmen:
$360.35M
Nettoeinkommen (Verlust:
$-149.57M
KGV:
-33.43
EPS:
-2.96
Netto-Cashflow:
$-81.27M
1W Leistung:
-3.68%
1M Leistung:
-17.24%
6M Leistung:
-22.68%
1J Leistung:
+11.01%
1-Tages-Spanne:
$94.15
$100.56
1-Wochen-Bereich:
$94.15
$105.07
52-Wochen-Spanne:
$89.94
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
Firmenname
Glaukos Corporation
Sektor
Branche
Telefon
949-367-9600
Adresse
1 GLAUKOS WAY, ALISO VIEJO, CA
Vergleichen Sie GKOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
98.82 | 5.49B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
131.62 | 225.32B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
100.58 | 149.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
374.08 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.55 | 113.49B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.03 | 42.10B | 5.72B | 4.17B | 259.90M | 6.97 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-19 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-12-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Eingeleitet | Truist | Buy |
| 2023-11-08 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-14 | Fortgesetzt | Stephens | Overweight |
| 2022-10-04 | Eingeleitet | Needham | Buy |
| 2022-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2022-02-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2021-11-03 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Hochstufung | Citigroup | Sell → Neutral |
| 2020-12-09 | Eingeleitet | Oppenheimer | Perform |
| 2020-11-17 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Eingeleitet | Jefferies | Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Sell |
| 2020-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Hochstufung | Berenberg | Hold → Buy |
| 2019-12-12 | Herabstufung | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Eingeleitet | BTIG Research | Neutral |
| 2018-08-30 | Eingeleitet | Berenberg | Hold |
| 2018-08-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Bestätigt | Stifel | Hold |
| 2018-06-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-01 | Bestätigt | Cantor Fitzgerald | Buy |
| 2017-03-02 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Hochstufung | Stifel | Hold → Buy |
| 2016-10-27 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Glaukos Corporation Aktie (GKOS) Neueste Nachrichten
The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals - TradingView
Learn to Evaluate (GKOS) using the Charts - news.stocktradersdaily.com
Glaukos CFO Thurman Alex R. sells $162k in stock By Investing.com - Investing.com South Africa
Glaukos CFO Thurman Alex R. sells $162k in stock - Investing.com
Glaukos Corporation (NYSE:GKOS) Is Expected To Breakeven In The Near Future - simplywall.st
Breakeven On The Horizon For Glaukos Corporation (NYSE:GKOS) - Yahoo Finance
Primecap Management Co. CA Has $182.08 Million Position in Glaukos Co. (NYSE:GKOS) - MarketBeat
First Week of May 16th Options Trading For Glaukos (GKOS) - Nasdaq
(GKOS) Trading Report - Stock Traders Daily
Glaukos, RadiusXR, and Topcon Healthcare Work to Advance Vision Testing - Medical Product Outsourcing
RadiusXR and Glaukos Announce a New Collaboration With Topcon Healthcare, Inc., and the Launch of Inspire - Vision Monday
Here's Why You Should Retain Glaukos Stock in Your Portfolio - MSN
Glaukos Licenses Iveena’s Investigational Keratoconus Therapy - Business Wire
Midday Stock Roundup: Xponential Fitness Plunges 38%, GEN Restaurant Group Up 10% - Orange County Business Journal
Glaukos Highlights Strategic Focus in 2024 Presentation - TipRanks
RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution - 01Net
Glaukos, RadiusXR collaborate with Topcon Healthcare on vision testing platform - TipRanks
Glaukos Unveils Game-Changing Vision Diagnostic Wearable: First-Ever Platform for Glaucoma Testing - Stock Titan
Where are the Opportunities in (GKOS) - news.stocktradersdaily.com
US Bancorp DE Acquires 470 Shares of Glaukos Co. (NYSE:GKOS) - Defense World
Glaukos Co. (NYSE:GKOS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Glaukos Corp. to Host Earnings Call - ACCESS Newswire
289 Shares in Glaukos Co. (NYSE:GKOS) Bought by IFP Advisors Inc - Defense World
Bank of New York Mellon Corp Increases Holdings in Glaukos Co. (NYSE:GKOS) - Defense World
Is Glaukos Corporation (GKOS) the Best Medical Technology Stock to Buy According to Analysts? - Insider Monkey
Glaukos, Tarsus, RxSight: Q4 Earnings Snapshot - Orange County Business Journal
Stifel maintains Buy on Glaukos stock, reiterates $175 target By Investing.com - Investing.com South Africa
Stifel maintains Buy on Glaukos stock, reiterates $175 target - Investing.com
Truist Financial Corp Sells 5,319 Shares of Glaukos Co. (NYSE:GKOS) - Defense World
7 Best Medical Technology Stocks To Buy According To Analysts - Insider Monkey
Glaukos CEO Makes a Multi-Million Dollar Stock Sale! - TipRanks
Glaukos director Mark Foley sells common stock for $2.5 million By Investing.com - Investing.com Australia
Glaukos director Mark Foley sells common stock for $2.5 million - Investing.com
GKOS Crashes Almost 25% After Q4 Earnings: How to Play the Stock? - MSN
Glaukos Corporation (NYSE:GKOS) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless - Simply Wall St
(GKOS) Investment Report - Stock Traders Daily
Glaukos Co. (NYSE:GKOS) Shares Sold by Taylor Frigon Capital Management LLC - MarketBeat
FDA accepts Glaukos application for Epioxa for keratoconus - MSN
CIBC Asset Management Inc Makes New Investment in Glaukos Co. (NYSE:GKOS) - Defense World
Needham & Company LLC Forecasts Strong Price Appreciation for Glaukos (NYSE:GKOS) Stock - MarketBeat
GLAUKOS Corp SEC 10-K Report - TradingView
FDA sets review date for Glaukos’ keratoconus drug By Investing.com - Investing.com Australia
GKOSGlaukos Corp Latest Stock News & Market Updates - StockTitan
FDA gives Glaukos ‘Day 74’ notice for Epioxa NDA to treat keratoconus - TipRanks
Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today - Benzinga
FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery - Benzinga India
Glaukos Announces FDA Acceptance Of NDA Submission For Epioxa(TM) -February 24, 2025 at 08:24 am EST - Marketscreener.com
Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™ - BioSpace
FDA sets review date for Glaukos' keratoconus drug - Investing.com India
Glaukos's Corneal Disease Drug Accepted for FDA Review -February 24, 2025 at 07:33 am EST - Marketscreener.com
FDA sets review date for Glaukos' keratoconus drug By Investing.com - Investing.com South Africa
Finanzdaten der Glaukos Corporation-Aktie (GKOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.76%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):